dilatrend
f. hoffmann-la roche ltd. - carvedilol - tablets - 25mg
avastin 25mg/ml concentrate for solution for infusion
roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml
avastin 25mg/ml concentrate for solution for infusion
roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml
cellcept capsules
f. hoffmann-la roche ltd. - mycophenolate mofetil - capsules - 250mg
neupogen injection 480 mcg1.6 ml
amgen biotechnology singapore pte ltd - filgrastim - injection - 480 mcg/1.6 ml - filgrastim 480 mcg/1.6 ml
bonviva tablets film-coated
f. hoffmann-la roche ltd. - ibandronic acid (ibandronic acid monosodium monohydrate) - tablets film-coated - 150mg
actemra 162 mg s.c.
roche pharmaceuticals (israel) ltd - tocilizumab - solution for injection - tocilizumab 162 mg / 0.9 ml - tocilizumab - - actemra in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (dmards) or tumor necrosis factor (tnf) antagonists. in these patients, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. - actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx - actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (gca) in adult patients. - actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. actemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.
vabysmo
roche pharmaceuticals (israel) ltd - faricimab - solution for injection - faricimab 120 mg/ml - faricimab - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with:• neovascular (wet) age-related macular degeneration (namd) • diabetic macular edema (dme)
zelboraf
roche pharmaceuticals (israel) ltd - vemurafenib - film coated tablets - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.
recormon
roche diagnostics gmbh sandhofer strasse 116 d-68305 mannheim for f. hoffmann-la roche ltd. - epoetin beta - solution for i/v and s/c injection - 2000iu/0,3ml